Lipophilic drugs intestinal lymph

By enhancing the formation and turnover of lymph lipoproteins through the enterocyte and provoking, or improving, the targeting of orally administered lipophilic drugs to the intestinal lymphatics. 

The consequences of intestinal lymphatic transport are therefore more wide ranging than the opportunity to target the intestinal and central lymph and to avoid first-pass metabolism. Indeed, drug transport by means of the intestinal lymph may markedly alter the patterns of subsequent systemic drug clearance and disposition, and these profound alterations could be stimulated simply by a change in formulation. Importantly, the common approach of the use of plasma AUC as an indicator of the available fraction may be misplaced when dealing with lipophilic and lymphotropic drug molecules. 

---